Heparin inhibits thrombin-induced mitogen-activated protein kinase signaling in arterial smooth muscle cells  by Hedin, Ulf et al.
512
Smooth muscle cell (SMC) proliferation con-
tributes to the development of atherosclerotic and
restenotic lesions,1 and much effort has been devot-
ed to the identification of factors that modulate this
process. Heparin inhibits SMC proliferation both in
vitro2 and in vivo after arterial injury in rats.3 The
mechanisms involved in the growth inhibitory prop-
erties of heparin are not completely known. Heparin
acts in several phases of the cell cycle.4,5 Heparin can
inhibit protein kinase C (PKC)-dependent mito-
genic signals,6 it may prevent induction of early
response genes,7,8 and it inhibits interactions
between transcription factors and DNA.9 In addi-
tion, heparin can modulate growth factor activity by
binding to growth factors.10
Serum-induced signaling by the mitogen-activat-
ed protein kinase pathway (MAPK) was recently
shown to be inhibited by heparin in rat SMCs11 and
in rat mesangial cells.8 Such a mechanism could
explain the ability of heparin to prevent transition of
cells through the G1 phase of the cell cycle.
p42MAPK and p44MAPK are members of the MAPK
family of protein kinases, which transduce signals
from different growth factor receptors.12 Activation
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of these MAPKs is mediated by MAPK kinases
(MAPKKs), which become engaged by signaling
from growth factor receptors by activation of the
small GTPase Ras and the upstream activator of
MAPKK, Raf-1.12 The ability of different growth
factors to promote DNA synthesis has been suggest-
ed to depend on sustained MAPK activity and the
translocation of p42MAPK and p44MAPK from the
cytoplasm to the nucleus.13,14
We have recently shown that heparin inhibits
serum-induced MAPK activity in baboon SMCs at
the level of or upstream of MAPKK-1, whereas no
inhibition occurred in signals elicited by stimulation
of tyrosine kinase receptors by the polypeptide
growth factors platelet-derived growth factor BB and
basic fibroblast growth factor.15 In a similar fashion
heparin has been shown to inhibit serum- and phor-
bol-12-myristate-13-acetate-induced MAPK activity
but not epidermal growth factor-induced kinase
activity in rat SMCs.11 Taken together, these results
indicate that heparin does not inhibit growth signals
induced by activation of tyrosine kinase receptors. In
this study we examined whether heparin instead
interferes with another class of growth agonists.
Because growth regulation by the MAPK pathway
also involves seven transmembrane receptors coupled
to heterotrimeric G-proteins,16 we analyzed the
effect of heparin on the activity of the MAPK path-
way and DNA synthesis in baboon SMCs stimulated
with thrombin and other G-protein agonists.
METHODS
Reagents. Monoclonal antibodies against
MAPKK-1 were purchased from Transduction
Laboratories (Lexington, Ky.), and 3H-thymidine
and 32P- g -adenosine triphosphate were purchased
from Du Pont-New England Nuclear (Boston,
Mass.). Myelin basic protein and catalytically inactive,
histidine-tagged p42MAPK (K52R mutant) were pre-
pared with minor modifications as described.17,18
Human a -thrombin was purchased from American
Diagnostica Inc. (Greenwich, Conn.). Prestained
molecular weight marker for sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE),
human endothelin-1 (ET-1), human angiotensin II
(AT II), L-a -lysophosphatidic acid (LPA), the throm-
bin receptor agonist peptide SFLLRNPNDKYEPF
(TRAP), hirudin from leeches, protein A agarose,
phorbol-12-myristate-13-acetate (PMA), chondroitin
sulfate, heparin sulfate, and unfractionated heparin
from porcine intestinal mucosa were purchased from
Sigma (St. Louis, Mo.). A rabbit antiserum recogniz-
ing p42MAPK and p44MAPK as previously determined
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by immunoblotting (7884) was a generous gift from
R. Seger,19 and goat serum and fluorescein isothio-
cyanate-conjugated goat anti-rabbit immunoglobulin
G were from Cappel (Malverne, Pa.).
Cell culture. SMCs were isolated from baboon
aortic media, used in passage 5 to 15, and cultured
in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum (Gibco),
200 U/ml penicillin, and 0.2 mg/ml streptomycin.
Confluent cultures were detached with 0.1% trypsin
and 0.02% ethylenediamine tetraacetic acid in
Dulbecco’s phosphate buffered saline solution (PBS;
pH 7.4) and reseeded in multiwell plates at 20,000
cells/cm2 in DMEM/10% fetal bovine serum. After
24 hours of culture the cells were serum-starved for
3 days in DMEM/Ham’s nutrient mix F-12 supple-
mented with 5 mg/ml transferrin, 1 mg/ml bovine
serum albumin, 200 U/ml penicillin, and 0.2
mg/ml streptomycin (DMEM/F-12). In experi-
ments with LPA the concentration of bovine serum
albumin was raised to 10 mg/ml.
MAPK assay. SMCs cultured in 12-well plates
were serum-starved for 72 hours in DMEM/F-12.
The cells were thereafter stimulated as indicated in the
text, washed twice with ice-cold PBS, and harvested
in 25 mmol/L N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid (HEPES), pH 7.5, 10% glycerol,
5 mmol/L ethylenediamine tetraacetic acid, 5
mmol/L ethyleneglycol-bis-( b -aminoethylether)-
N,N,N’,N,-tetraacetic acid, 150 mmol/L NaCl, 100
mmol/L Na-pyrophosphate, 50 mmol/L NaF, 1
mmol/L Na-vanadate, 1 mmol/L benzamidine, 0.1%
2 b mercaptoethanol, 1% Triton X-100, 1 mmol/L
pepstatin A, 2 mg/ml leupeptin, and 20 kallikrein
inhibitor U/ml aprotinin. To 1 vol of lysate, 0.5 vol
4 · Laemmli buffer and 0.15 vol 20% SDS were
added. MAPK activity was measured with an in-gel
phosphorylation assay as previously described.20,21 In
brief, 10 to 50 mg protein were subjected to SDS-
PAGE with 10% gels that were polymerized in the
presence of 0.25 mg/ml myelin basic protein. After
electrophoresis was performed, the gels were incubat-
ed for 1 hour at room temperature in 50 mmol/L
HEPES-NaOH, pH 7.5, 20% 2 propanol followed by
buffer A (50 mmol/L HEPES-NaOH, pH 7.5, 5
mmol/L 2 b mercaptoethanol) with one change of
each solution. Protein was denatured by immersing
the gels in buffer A containing 6 mol/L urea twice for
15 minutes and renatured overnight at 4° C in buffer
A containing 0.05% Tween-20 with two buffer
changes. After a 30-minute incubation at room tem-
perature in kinase buffer (20 mmol/L HEPES-
NaOH, 20 mmol/L MgCl2, 2 mmol/l dithiothre-
itol), phosphorylation was performed by soaking
the gels for 45 minutes in kinase buffer containing
20 mmol/L 32P- g -adenosine triphosphate (1000 
to 2000 cpm/pmol). Nonbound radioactivity 
was removed by six 30-minute washes with 
5% trichloroacetic acid (TCA) and 1% sodium
pyrophosphate. Before drying, the gels were stained
with Coomassie Blue G to control for equal loading
of protein. Incorporated radioactivity was analyzed
by phosphoimaging (facility at the University of
Washington, Department of Pharmacology). The
sum of activities of p42MAPK and p44MAPK are
referred to as MAPK activities. For statistical analy-
sis differences were normalized to maximum activi-
ty at each time point and expressed as mean ± SD,
and comparisons were made with paired Mann-
Whitney-U test with significance level set to 
p < 0.05.
MAPKK assay. SMCs cultured in 100 mm
petri dishes were serum-starved for 72 hours, stimu-
lated as indicated in the text, and harvested as
described previously for MAPK assays. The lysate
was kept on ice for 20 minutes, vigorously mixed,
and spun for 5 minutes at maximum speed in a
microfuge. One milligram of MAPKK-1 antibody
and 10 ml of protein A sepharose slurry (1 mg/ml
protein A) were added to the supernatant containing
0.1 to 0.5 mg protein. The sample was stirred
overnight at 4° C or for 4 hours at room tempera-
ture. The beads were washed in buffer HEB fol-
lowed by two washes in 25 mmol/L TRIS-HCl pH
7.5, 500 mmol/L NaCl, 0.1% Triton X-100, 0.1% 2
b mercaptoethanol and one wash in buffer K (50
mmol/L HEPES, pH 7.5, 10 mmol/L MgCl2,
0.1% Triton X-100, 0.1% 2 b mercaptoethanol). The
kinase reaction on the beads was performed in buffer
K containing 1 mg (K52R)-MAPK-2 per assay and
50 mmol/L 32P- g -adenosine triphosphate (5000
cpm/pmol). The assay was incubated for 30 to 45
minutes at a room temperature or 30° C. The reac-
tion was terminated by adding 10 ml 4 · Laemmli
buffer, the samples were subjected to SDS-PAGE,
and the extent of MAPK phosphorylation was deter-
mined as described previously for MAPK in-gel
assays. Assays were performed in duplicates.
Analysis of DNA synthesis. SMCs cultured in
24-well plates were serum-starved in DMEM/F-12
for 3 days and stimulated in quadruplicates as indi-
cated in the text in the presence of 1 mCi/ml 3H-
thymidine for 24 to 48 hours. The wells were rinsed
twice in ice-cold PBS and macromolecular material
precipitated in 10% TCA overnight at 4° C. After
repeated washes were performed in TCA, the cells
were lysed in NaOH for 1 hour, and radioactivity
was measured by liquid scintillation counting.
Immunofluorescence microscopy. SMCs were
seeded on glass coverslips and cultured as described
previously. After stimulation was performed with
mitogens, the cells were fixed in 4% formaldehyde in
PBS for 20 minutes at 20° C and permeabilized by
incubation in 0.1% SDS for 1 minute. After rinsing
in PBS, aldehyde groups were reduced by incuba-
tion in 0.15 mol/L glycine twice for 15 minutes.
Nonspecific binding was blocked by 30-minute
incubation in 5% goat serum, 0.05% Tween-80 in
PBS. The specimens were then exposed to a rabbit
antiserum against p42MAPK and p44MAPK (7884;
1:3000) diluted in PBS with 3% bovine serum albu-
min overnight at 4° C. After washing in PBS for 3 ·
15 minutes, the specimens were incubated in fluo-
rescein isothiocyanate-labeled secondary antibodies
(1:40) for 2 hours at 20° C. After rinsing in PBS, the
specimens were mounted in Vectashield (Vector,
Burlingame, Calif.), studied in a Nikon microscope
with epifluorescence optics, and photographed with
Kodak T-max film.
RESULTS
Heparin inhibits thrombin-induced MAPKK-
1 and MAPK activity and prevents translocation
of MAPKs to the nucleus in baboon SMCs.
MAPK and MAPKK-1 activity was examined in the
same samples after stimulation with 10 nmol/L
thrombin in the absence or presence of 0.1 mg/ml
heparin (Fig. 1, A, B, C). Thrombin activated both
kinases in a biphasic manner. An early transient peak
of activity was observed 5 to 15 minutes after stim-
ulation followed by a second, more sustained peak of
activity 45 minutes after stimulation, which
remained above basal levels for 2 to 3 hours.
Heparin inhibited the second peak of kinase activity
but did not affect the first peak. The addition of
heparin 10 minutes before or after the addition of
thrombin to the cells did not alter the inhibitory
capacity of heparin (not shown).
Analysis of DNA synthesis showed that heparin
caused a complete inhibition of DNA synthesis
induced by thrombin. A dose-dependent increase in
3H-thymidine incorporation was observed after a
48-hour incubation with thrombin at 1 to 100
nmol/L, which was blocked by heparin (Fig. 1, D).
The proteolytic activation of thrombin receptor sig-
naling was confirmed by inhibition of the catalytic
site of thrombin with a twofold excess of hirudin.
This pretreatment completely abolished induction of
MAPK activity and DNA synthesis by thrombin (not
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Fig. 1. Inhibition of thrombin-induced growth signals by heparin. Time course of MAPK
activity (A and B) and MAPKK-1 activity (C) after stimulation of serum-starved baboon
SMCs with 10 nmol/L thrombin in presence (solid squares) or absence (empty squares) of 0.1
mg/ml heparin and effect of 0.1 mg/ml heparin on DNA synthesis induced by increasing
concentrations of thrombin (D). A shows autoradiograph of MAPK activity from typical
time course experiment. In B and C MAPK and MAPKK-1 activity were assayed from same
samples as described in Methods and data obtained by phosphoimager analysis. Results are
related to maximum activity and presented as mean ± SD of three experiments. DNA synthe-
sis was analyzed by 3H-thymidine incorporation for 48 hours, and results are presented as
mean ± SD of four samples.
A
JOURNAL OF VASCULAR SURGERY
516 Hedin et al. March 1998
shown). The effect of heparin on MAPK activity was
found to be dose-dependent with a 50% inhibition at
10 m g/ml and specific because only a minor reduc-
tion in activity was observed at high concentrations
of chondroitin sulphate, another polyanionic glu-
cosaminoglycan (Fig. 2). Inhibition of thrombin-
induced MAPK activity was also obtained with
heparin sulphate at 0.1 mg/ml (not shown).
To investigate whether prevention of thrombin-
induced DNA synthesis by heparin affected MAPK
translocation to the nucleus, we analyzed p42MAPK
and p44MAPK distribution in SMC by immunocyto-
chemistry. Stimulation of SMCs with 10 nmol/L
thrombin for 1 hour was accompanied by an
increased immunoreactivity in the nucleus (Fig. 3,
A), whereas nuclear staining was reduced in cells
stimulated with thrombin in the presence of 0.1
mg/ml heparin (Fig. 3, B).
Thrombin-induced DNA synthesis in baboon
SMCs requires sustained MAPK activity. Our
conclusion that heparin prevented thrombin-stimu-
lated DNA synthesis by inhibiting sustained MAPK
activity was supported by experiments with the
thrombin receptor agonist peptide SFLLRNPND-
KYEPF (TRAP). Whereas thrombin mediated a
biphasic activation of MAPK, the effect of TRAP was
transient. At 20 m mol/L, TRAP induced an early
peak similar to 10 nmol/L thrombin, but no pro-
longed MAPK activity was observed (Fig. 4, A). In
addition, TRAP stimulation only transiently activated
MAPKK-1 (not shown). Heparin did not affect
TRAP-induced MAPK activity (Fig. 4, A). The dif-
ferent patterns of kinase activity after stimulation
with thrombin and TRAP were also reflected in the
ability of these agents to induce DNA synthesis. In
contrast to thrombin, TRAP did not promote DNA
synthesis in baboon SMCs (Fig. 4, B).
Heparin inhibits thrombin-induced MAPK
activity by a protein kinase C independent path-
way. Treatment of baboon SMCs with phorbol
ester results in the downregulation of classic calci-
um- and lipid-dependent PKC isoforms PKC a, g, d,
and e.7,15 Here, we used PMA pretreatment to
examine the role of PKC in heparin inhibition of
thrombin-induced MAPK activity. In SMCs treated
with 1 m mol/L PMA for 24 hours, early MAPK acti-
vation by thrombin was abolished. However, a par-
Fig. 2. Heparin specifically inhibits thrombin-induced
MAPK activity. Serum-starved SMCs were stimulated for
30 minutes with 10 nmol/L thrombin together with
increasing concentrations of heparin (solid squares) or
chondroitin sulphate (empty squares). MAPK activity was
analyzed with myelin basic protein in gel assay and phos-
phoimager analysis as described in Methods. Results are
related to maximum activity and presented as mean of
duplicate samples.
Fig. 3. Heparin inhibits thrombin-induced nuclear
translocation of p42MAPK/p44MAPK. Serum-starved
SMCs were stimulated for 1 hour with 10 nmol/L throm-
bin in absence (A) or presence (B) of 0.1 mg/ml heparin
and prepared for immunocytochemistry with antiserum
against p42MAPK/p44MAPK.
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tial recovery of kinase activity could be observed 30
to 60 minutes after thrombin stimulation. This
activity remained sensitive to heparin inhibition. At
45 minutes an 83.5% ± 17.4% (p = 0.034; n = 4)
inhibition was observed, and at 60 minutes kinase
activity was reduced by 84.3% ± 2.3% (p = 0.021; n
= 4; Fig. 5).
Heparin inhibits G-protein dependent mito-
genic pathways in baboon SMCs. To examine
whether growth inhibition by heparin included
other activators of heterotrimeric G-proteins, we
used LPA, ET-1, and AT II. LPA-induced MAPK
activity was of equal magnitude compared with
thrombin, whereas ET-1 and AT II were less effec-
tive. In all cases heparin significantly inhibited late
kinase activity at 30 and 60 minutes (Fig. 6. A, B).
Analysis of 3H-thymidine incorporation showed that
both LPA and ET-1 induced DNA synthesis in a
dose-dependent fashion with optimal concentrations
at 10 m mol/L and 0.4 m mol/L, respectively, where-
as AT II failed to promote DNA synthesis. LPA was
as potent as thrombin, and ET-1 was a considerably
weaker mitogen. Heparin prevented both LPA- and
ET-1-induced DNA synthesis (Fig. 6, C).
DISCUSSION
We have previously shown that heparin suppress-
es serum-induced MAPK activity and DNA synthe-
sis in baboon SMCs. In contrast, it had no inhibito-
ry effect when platelet-derived growth factor-BB
and basic fibroblast growth factor were used as mito-
gens.15 These results indicate that heparin targeted
growth stimulatory pathways that did not include
activation of receptor tyrosine kinases. Here, we pro-
vide evidence that heparin inhibits growth factor sig-
nals mediated by activation of heterotrimeric G-pro-
teins. Heparin prevented induction of sustained
MAPK activity by thrombin, LPA, ET-1, and AT II
and completely blocked DNA synthesis induced by
all these agents except AT II, which had no mito-
genic effect. Inhibition also occurred at the level of
MAPKK-1, suggesting that heparin does not direct-
ly affect MAPK activity. Finally, heparin prevented
translocation of p42MAPK/p44MAPK to the nucleus,
which is in agreement with the inhibition of pro-
longed MAPK activity in the presence of this com-
Fig. 5. Heparin inhibits thrombin-induced MAPK activ-
ity in PMA pretreated SMCs. MAPK activity 45 (white
bars) and 60 (black bars) minutes after stimulation with 10
nmol/L thrombin in presence or absence of 0.1 mg/ml
heparin in cells with or without previous incubation with
1 m mol/L PMA. Data was obtained by phosphoimager
analysis, presented as mean ± SD of four experiments, and
comparisons were made with paired Mann-Whitney-U
test with significance level (*) set to p < 0.05.
Fig. 4. Insufficient growth signaling by thrombin recep-
tor agonist peptide in baboon SMCs. A, Serum-starved
cells were stimulated with 10 nmol/L thrombin (empty
circles) or 10 m mol/L thrombin receptor agonist peptide
SFLLRNPNDKYEPF (TRAP) in presence (solid squares)
or absence (empty squares) of 0.1 mg/ml heparin and
MAPK activity analyzed as described in Methods. Data
obtained by phosphoimager analysis are related to maxi-
mum activity and presented as mean ± SD of three experi-
ments. B, DNA synthesis induced by thrombin and TRAP
in presence or absence of 0.1 mg/ml heparin was analyzed
by 3H-incorporation during 48 hours, and results are pre-
sented as mean ± SD of quadruplicate samples.
sitivity has also been described in different strains of
SMCs isolated from humans.23 The diverse effects of
heparin are further demonstrated by the observa-
tions that heparin prevents intimal hyperplasia after
balloon injury in rats but not in baboons, despite the
fact that SMCs from both species are growth-inhib-
ited in a similar fashion by heparin in vitro.3,15,24
Because different heterotrimeric G-proteins have
been shown to use different pathways to activate the
MAPK/MAPKK signaling module,25 it is difficult
to predict the molecular mechanisms responsible for
the inhibitory effect of heparin. However, the abili-
ty of heparin to inhibit thrombin-induced MAPK
activity in SMCs pretreated with PMA suggests that
heparin did not directly act through a PKC isoform
that is affected by PMA. This finding supports our
previous results in serum-stimulated baboon SMCs
and recent observations in rat mesangial cells.8,15 In
contrast, the inhibitory effect of heparin has been
linked to PMA-sensitive PKC isoforms in rat
SMCs.7,26 This discrepancy might indicate a species-
or cell specific role of some PKC isoforms.
The fact that heparin mainly inhibited the second
peak of thrombin-mediated MAPK-activation,
nuclear translocation of MAPKs, and DNA synthesis
supports the idea that sustained MAPK activity is
necessary for cell cycle progression.13,14 This con-
clusion was also confirmed by the different patterns
of MAPK activation by thrombin and TRAP and the
diverse effects of these agents on DNA synthesis. We
found a close correlation between thrombin-
induced DNA synthesis and the activation of MAPK
and MAPKK-1. Previously, thrombin has been
shown to activate the MAPK pathway in rat SMCs,27
and downregulation of MAPK proteins has also
been shown to impair thrombin-induced DNA syn-
thesis in fibroblasts.28 The prolonged second phase
of thrombin-induced kinase activity appeared to be
necessary for DNA synthesis, because TRAP, at a
concentration that stimulated an early peak of
MAPK activity comparable to thrombin, failed to
elicit sustained kinase activity and lacked mitogenic
effect. As expected, heparin did not affect TRAP-
induced MAPK activity. The diverse effects of
thrombin and TRAP on MAPK induction and mito-
genesis have previously been demonstrated in
fibroblasts.29 In contrast, others have shown that
TRAP can mimic the mitogenic capacity of throm-
bin in SMCs.27,30 However, much higher concen-
trations of the peptide were used in those studies.
Thrombin and other agonists of heterotrimeric
G-proteins have been proposed to contribute to
SMC proliferation in atherogenesis and vascular
JOURNAL OF VASCULAR SURGERY
518 Hedin et al. March 1998
pound. The effect of heparin was specific because
the same concentration of chondroitin sulphate, a
related polyanionic glycosaminoglycan, was not
inhibitory. In human SMCs the ability of heparin to
interfere with thrombin-induced mitogenesis has
been shown to be dependent on the presence of
antithrombin,22 and a heterogeneity in heparin sen-
Fig. 6. Heparin inhibits MAPK activity and DNA syn-
thesis in SMCs stimulated with heterotrimeric G-protein
agonists. MAPK activity in SMCs stimulated for 30 (A)
and 60 (B) minutes with 10 nmol/L thrombin (white
bars, 0.4 m mol/L ET-1 (grey bars), 10 m mol/L LPA
(black bars), and 200 nmol/L AT II (hatched bars) with or
without 0.1 mg/ml heparin. A and B show data obtained
by phosphoimager analysis, presented as mean ± SD of
three experiments, and comparisons made with paired
Mann-Whitney-U test with significance level (*) set to p <
0.05. C, DNA synthesis induced by 10 m mol/L LPA, 0.4
m mol/L ET-1, and 200 nmol/l AT II in presence (black
bars) or absence (white bars) of 0.1 mg/ml heparin. DNA
synthesis was analyzed by 48-hour incubation with 3H-
thymidine, and data are presented as mean ± SD of qua-
druplicate samples.
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repair,31-33 and both thrombin and LPA have been
suggested to be part of the growth stimulatory prop-
erty of serum.34,35 AT II was not a mitogen for
baboon SMCs in vitro, but this may reflect species
differences because AT II promotes SMC prolifera-
tion in other species,36 and it has been suggested to
be involved in lesion development after arterial
injury.32 In animal models inhibitors of AT II and
thrombin also prevent luminal narrowing after arter-
ial injury.37,38 Heparin has been shown to prevent
SMC proliferation in vivo after arterial injury in the
rat.3 This inhibition might be partly attributed to the
ability of heparin to bind and displace basic fibroblast
growth factor.10 This study contributes new informa-
tion regarding the growth inhibitory mechanisms of
heparin and suggests that heparin may also block sig-
naling by heterotrimeric G-protein agonists such as
thrombin and AT II after arterial injury.
We thank Melanie Cobb for the plasmid encod-
ing of the his-tagged K52R-ERK2 mutant, Rony
Seger for ERK antiserum 7884, and Alexandra
Dumitrescu for technical assistance.
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